GoKawiilResearchers detail small-molecule METTL1 inhibitor effective against solid and blood cancers
A new study presents a pharmacological inhibitor targeting METTL1, an enzyme that modifies RNA, and reports that blocking its activity suppresses growth in both solid tumour and blood cancer models. The paper also describes the biochemical methods used, including expression and purification of the full-length METTL1–WDR4 protein complex, to support structural and functional characterization of the drug target.
GoKawiil's interpretation of the reporting above, not reported fact.
METTL1 has been studied as a regulator of tRNA modification linked to cancer cell proliferation, so a working small-molecule inhibitor could open a new therapeutic avenue if validated in further preclinical and clinical testing. The detailed structural and purification work suggests researchers are building toward rational drug design against this target, though translation to approved therapies would require extensive additional validation.
- A pharmacological inhibitor of METTL1 was tested against both solid tumour and blood cancer models.
- Researchers purified the full METTL1–WDR4 complex to support drug-target studies.
- The work represents early-stage research rather than a clinically approved treatment.
Source: nature.com — Yankova, 2026-10-28
Published there as: “Pharmacological inhibition of METTL1 as a therapy against solid and blood cancers”
Read the original report → The summary and analysis above are GoKawiil's own, written from reporting by the source above. Facts and quotes belong to the original publisher.